ABT-239 is an H3-receptor inverse agonist developed by Abbott. It has stimulant and nootropic effects and has been investigated as a treatment for ADHD Alzheimer’s disease and schizophrenia. ABT-239 is more active at the human H3 receptor than comparable agents such as thioperamide ciproxifan and cipralisant.
This page contains content from the copyrighted Wikipedia article "ABT-239"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
